Newsroom

Press Release

NeoGenomics Appoints Dave Daly to Its Board of Directors

NeoGenomics Announces Leadership Team Transition

NeoGenomics Reports Revenue of $121 Million in the Third Quarter

NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays

NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR™ MRD and InVisionFirst®-Lung Assays at the ESMO Congress 2021

NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021

NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients